27.8 C
Vientiane
Saturday, July 5, 2025
spot_img
Home Blog Page 1114

Hansen Strengthens Community Solar Reach Across the United States, Targets New Growth Opportunities

Hansen today partners with Community Solar developers across ten US states; primed to enter seven more as customer operations expand

MELBOURNE, Australia, Jan. 14, 2025 /PRNewswire/ — Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, utilities, communications, and media industries, is proud to announce that its Hansen CIS Community Solar Solution now supports customers across ten US states, with Colorado and Illinois being the latest additions to its expanding footprint.

These two states are investing significantly to enable access for more Americans to more renewable energy options. Colorado has its Colorado Solar for All program and is focused on modernizing its Community Solar program; Illinois aims to have 50 per cent of its electricity sourced from renewable sources by 2040, with initiatives ranging from its Future Energy Jobs Act and Illinois Solar for All.

According to a recent study by the NREL (National Renewable Energy Laboratory), the technical potential for community solar in the United States points to Community Solar theoretically growing to serve all residential electricity customers who are unable to adopt behind-the-meter solar power, including low- to moderate-income households.

Bobby Slaton, Executive Vice President, Americas for Energy & Utilities at Hansen explains: “Community Solar opens up the ability to be part of the renewable energy future to all Americans. Strong software developers like Hansen are best-placed to support the developers of community solar farms with software that complies with state-by-state legislation. Hansen is proud to have been an early entrant in the Community Solar market, managing solar farm customer acquisition and management through its scalable and secure software platform.”

Veteran solar developer and infrastructure company, Cenergy Power, is leveraging Hansen’s Community Solar Solution in Maine, with plans to expand into other states.

Chad Chahbazi, Senior Vice President for Project & Business Development at Cenergy Power, says: “At Cenergy, we required secure, scalable, and best-of-breed software solutions, for our Community Solar assets. We have found a like-minded partner in Hansen. With their track record of excellence, rolling out specific solutions for Community Solar providers in the United States, their product suite addresses our needs – for both the present and the future. Additionally, their market knowledge and commercial focus with respect to community solar asset management makes them an excellent partner for us.”

Gridwealth, formerly Hampshire Power, Nautilus Energy and MC2 are among other Community Solar providers who are expanding across the United States with Hansen. Areas include the States of Colorado, Minnesota, Illinois, Massachusetts, New York, Maine, Rhode Island, New Jersey, Delaware, and Maryland. Hansen is ready to support customers as they further expand into Washington, Oregon, Nevada, California, New Mexico, Virginia, and New Hampshire.

To learn more about Hansen, and its Community Solar Solution, visit www.hansencx.com.

About Hansen
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water, and communications industries. With its award-winning software portfolio, Hansen serves customers in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com

Endogenex™ Appoints Krissy Wright as Chief Financial Officer

Bringing finance, operational, and corporate development expertise to an experienced leadership team.

MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/  Endogenex, Inc., a clinical-stage medical device company, is proud to announce the addition of Krissy Wright as Chief Financial Officer (CFO). In this role, Wright will lead Endogenex’s financial strategy, corporate development initiatives, and operational planning to support the advancement of the company’s clinical initiatives.

“We are thrilled to welcome Krissy to the Endogenex leadership team,” said Stacey Pugh, CEO of Endogenex. “Her extensive experience in financial strategy, corporate development, and leadership in the MedTech industry will be instrumental as we work to achieve our clinical milestones and deliver transformative solutions to type 2 diabetes management.”

Krissy brings experience from Cleerly, an AI-driven heart diagnostics company, where she served as CFO, and from Medtronic, where she held leadership roles including Vice President and General Manager of Brain Modulation and Vice President and Chief Financial Officer for the Neuromodulation Operating Unit. Earlier in her career, she spent 11 years at PricewaterhouseCoopers, specializing in Audit, Assurance, and Transaction Services.

“I am thrilled to be joining Endogenex at such a pivotal moment in its journey,” said Wright. “The company’s novel approach to addressing type 2 diabetes can potentially transform the lives of millions worldwide. I look forward to leveraging my financial expertise to support the team in advancing this groundbreaking therapy and achieving our mission of delivering meaningful, scalable healthcare solutions.”

The ReCET Procedure:
ReCET is a novel, endoscopic, outpatient procedure that targets the underlying cellular abnormalities in the duodenum that contribute to the development and progression of type 2 diabetes.

By applying highly controlled, non-thermal pulsed electric fields, the ReCET Procedure is designed to initiate the body’s natural regenerative process to restore proper cellular signaling from the duodenum and improve glycemic control.

The ReCET Procedure is currently being evaluated in global pre-commercialization trials assessing its safety and efficacy in adults with type 2 diabetes who are inadequately controlled despite the use of insulin and non-insulin medications. The ReCET Procedure has received Breakthrough Device Designation from the FDA for the treatment of type 2 diabetes in adult patients inadequately controlled by glucose-lowering medications.

About Endogenex:
Endogenex is a privately held, clinical-stage company headquartered in Minneapolis, MN. Endogenex was founded in partnership with Mayo Clinic to develop therapies to improve outcomes for people living with type 2 diabetes. Endogenex focuses on the principle that effective treatment for type 2 diabetes can extend beyond pharmaceutical options, correct metabolic function, and help people regain control of their blood glucose levels.

For more information, please visit our website at www.endogenex.com.

Media Inquiries:
Krissy Wright
kwright@endogenex.com
+1 651 329 5413

Logo – https://mma.prnasia.com/media2/2446687/2312_1673_DY23_ENDOGENEX_HORIZONTAL_LOGO_POSITIVE_CMYK_Logo_Logo.jpg?p=medium600

ZTE, Nokia, and Huawei Lead ABI Research’s 5G FWA CPE Vendor Competitive Ranking

LONDON, Jan. 14, 2025 /PRNewswire/ — A new Competitive Ranking by global technology intelligence firm ABI Research has found that ZTE is the leading 5G FWA CPE vendor, beating both Nokia and Huawei for the top spot overall and across both the innovation and implementation criteria. The assessment provides an in-depth, unbiased examination of ten CPE vendors’ 5G FWA CPE portfolios. The companies evaluated and ranked are:

Market Leaders: ZTE, Nokia, Huawei
Mainstream: Inseego, Zyxel, Ericsson, Tozed Kangwei, Vantiva
Followers:
Arcadyan, Cisco

“The 5G FWA market is rapidly growing and is now a proven monetization strategy for service providers. FWA of previous cellular generations was viewed as a backup or placeholder broadband technology for both the consumer and enterprise verticals; however, the advancements within both the 5G networks and CPE technology have allowed it to become considered a viable alternative to fixed broadband going forward,” explains Larbi Belkhit, Industry Analyst at ABI Research.

Ten criteria were chosen for this analysis, segmented between innovation and implementation clusters. These included the commercial success of the CPE vendor, value proposition offered, support and implementation, diversity of a vendor’s client base, KPIs of a flagship CPE, technological leadership, portfolio diversity, partnerships, network management capabilities, and security features.

ZTE led the competitive ranking overall, closely followed by Nokia and Huawei. ZTE had strong scores across the innovation and implementation criteria, ranking first for both due to their commercial success and their latest flagship CPE – the G5 Ultra – which utilizes AI technology to improve bandwidth efficiency and lower network congestion.

“The growth in demand for 5G FWA services is leading to the necessity of improvements to the spectral efficiency of CPE that are made available to customers to ensure that service providers can continue expanding their client base without overloading the network. While the leaders in this competitive ranking are strong in the consumer segment, enterprise-focused vendors such as Inseego and Ericsson offer advanced network management capabilities, a technology that will become more necessary for service providers in the consumer space long term to offer high-end services for their FWA customers,” Belkhit concludes.

These findings are from ABI Research’s 5G FWA CPE Vendor Competitive Ranking report. This report is part of the company’s 5G, 6G & Open RAN research service, which includes research, data, and ABI Insights. Competitive Ranking reports offer a comprehensive analysis of implementation and innovation strategies to offer unparalleled insight into a company’s performance and standing compared to its competitors.

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info:

Global
Deborah Petrara
Tel: +1.516.624.2558
pr@abiresearch.com

Argon Medical Expands Oncology Product Offering with Acquisition of the SeQure® and DraKon™ Microcatheters

PLANO, Texas, Jan. 14, 2025 /PRNewswire/ — Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announces the acquisition of certain assets of Accurate Medical Therapeutics, Ltd., the manufacturer and distributor of the SeQure® and DraKon™ microcatheters, from Guerbet SA, a global leader in medical imaging. The addition of the SeQure and Drakon microcatheters to Argon’s portfolio extends the company’s oncology offering to include therapeutic devices and accessories. Argon is already well established in diagnostic oncology through its vast portfolio of biopsy devices.

Microcatheters such as SeQure and DraKon are commonly used by physicians to conduct interventional procedures in which therapeutic agents or devices are introduced into the small vessels delivering blood to a tumor or abnormality. As such, physicians often select a microcatheter for a procedure based on the catheter’s ability to navigate to the target and its compatibility with therapeutic agents or devices. Both the SeQure and Drakon catheters earned a strong reputation for being easy to navigate and broadly compatible. Further, SeQure is the only reflux control microcatheter designed to create a fluid barrier that directs the flow of therapeutic agents and devices toward the intended target.

“A microcatheter can make or break a procedure,” said Dr. Neal Khurana, MD. “A well-designed microcatheter determines whether you achieve precise navigation, efficient delivery of embolic materials, and ultimately, optimal patient outcomes. The DraKon and SeQure microcatheters have become preferred tools in my practice due to their dependable trackability through tortuous vessels, the performance of their hydrophilic coating, and their ability to deliver contrast and embolics efficiently, even through the smallest catheter sizes.” Dr. Khurana is a leading interventional radiologist and co-founder of EmboPartners, a physician-run organization that specializes in minimally invasive vascular embolization procedures for improved patient care.

“Adding the SeQure and DraKon microcatheters to our existing product portfolio marks an important first step in expanding the products we offer interventional oncologists beyond diagnostic procedures and into therapeutic delivery,” said George Leondis, President & CEO, Argon Medical. “As we do so, we also expand the ways in which we can improve the lives of patients and caregivers through the delivery of best-in-class medical devices and superior service, in alignment with our company mission.”

Following the close of this acquisition, Argon will transition manufacturing of the SeQure and DraKon catheters to the company’s primary manufacturing facility in Athens, Texas. Once complete, Argon intends to re-commercialize both microcatheters in all markets where they were sold previously and evaluate new opportunities to supply these products to new markets.

About Argon Medical

Since its founding in 1972, Argon Medical Devices has earned a reputation for delivering innovative products, superior service, and exceptional value for Interventional Radiologists, Vascular Surgeons, and Interventional Cardiologists worldwide. Argon is proud to have over 1,200 employees, and manufacture products in the United States in Texas, Illinois, New York, and Wisconsin. Argon brands are well-known globally, highlighted by the Option™ ELITE IVC Filter, the CLEANER™ Rotational Thrombectomy System, the BioPince™ Ultra Full-Core Biopsy Instrument, and SKATER™ Percutaneous Drainage Catheters. By utilizing a well-established sales and marketing infrastructure, Argon serves its global customers through a direct sales organization, and long-standing relationships with medical device distributors and strategic partners.

IFF Pharma Solutions Wins Pharmaceutical Technology Excellence Award

Recognized for brand leadership with its “Timing is Everything” controlled release platform for oral drug delivery.

NEW YORK, Jan. 14, 2025 /PRNewswire/ — IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, announced today that it has won the 2024 Pharmaceutical Technology Excellence Awards’ Brand Leadership category for its “Timing is Everything” campaign. The campaign features IFF’s newly designed controlled release platform, which provides customers with solutions at every turn.

This award recognizes “Timing is Everything” campaign for its strategic marketing tactics, creativity and leadership. The campaign focuses on building an integrated thought leadership platform for controlled release through storylines and cohesive branding. It includes a three-pronged approach with a social media teaser countdown, video and microsite.

“We are honored to receive this esteemed recognition for our ‘Timing is Everything’ campaign that highlights our controlled release portfolio,” said Lisa M. Miree-Luke, global communications director, IFF Pharma Solutions. “This award is a testament to our trailblazing products and the passionate teams behind them. METHOCEL™─Pioneering Then, Innovating Now; ETHOCEL™─Proven Time After Time and POLYOX™─Versatile Across Complex and Unique Applications, they are not just taglines but promises we stand by. We are committed to driving innovation, quality and helping to enable our customers’ successes.”

The “Timing is Everything” campaign elevates brand awareness and culminates in the creation of a best-in-class dedicated thought leadership platform for controlled release polymers in the excipients industry. The platform educates visitors about pharmaceutical formulations that benefit patients and the importance of controlled release of active ingredients through comprehensive materials such as white papers, webinars and articles.

The Pharmaceutical Technology Excellence Awards honors the most significant achievements and innovations in the pharmaceutical industry. Powered by GlobalData’s business intelligence, the awards recognize the people and companies leading change and shaping the future of the industry.

###

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.comLinkedInInstagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with TM, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contact:
Emily Kaufman
Global Communications Specialist
+1 9086705691
Emily.Kaufman@iff.com

Korea’s Leading Indie Beauty Brand d’Alba, Reaches New Heights Globally with 210% Overseas Sales Surge

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ — Premium vegan beauty brand d’Alba has achieved significant growth in its overseas sales, rising  to approximately KRW 150 billion won (USD 100 million) in 2024 – which is a 210% growth compared to the previous year. With this growth, d’Alba’s international market revenue now accounts for 45% of its total revenue.

Its global growth came from its flagship product, the White Truffle First Spray Serum, alongside Waterful Sunscreen and Double cream. d’Alba’s consistent performance across diverse global markets including Japan, ASEAN countries, US, EU, and Russia highlights its strong customer base and successful penetration into the international beauty scene.

d’Alba had been generating most of its sales from the Korean market until 2023. The First Spray Serum initially gained traction in Korea as the “Flight Attendant Mist” getting widely known with its innovative formulation based on premium ingredients like White Truffles with the convenience of a spray. With this product, the brand gained its leading position in the domestic market with notable references in the major beauty channels – top 3 at Olive Young, 1st rank in the Naver Shopping Beauty Category, and 1st rank in Coupang’s Suncare/Essence/Ampoule Category.

Previously recognized primarily for its strong domestic performance, d’Alba has swiftly transitioned to the global stage. In 2024, d’Alba’s overseas revenue climbed significantly to USD 110 mn from USD 35 mn in 2023. Now d’Alba’s global sales accounts for 45% of total sales whereas it was about 22% in 2023.

An industry expert commented, “While many K-beauty brands’ revenue rely on specific markets such as China, U.S, or Japan, d’Alba’s evenly distributed growth across Europe, Japan, North America, and ASEAN is a rarity. This positions them uniquely in the competitive landscape.”

Looking ahead, the brand is optimistic about the continued expansion, stating “These global markets are still at the early stage. We’re receiving many inquiries from large retail platforms worldwide. Our focus on channel expansion and the new products such as beauty devices will drive further growth.”

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ — ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for ‘Pemziviptadil (development code name PF1804),’ a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration (FDA).

Pemziviptadil is a once-weekly DMD cardiomyopathy drug developed based on ImmunForge’s long-acting drug platform, the ELP Platform (Elastin Like Polypeptide Platform). Pemziviptadil is a vasoactive intestinal peptide (VIP) that selectively acts on the vasoactive intestinal peptide receptor 2 (VPAC2) to increase both cardiac contraction and relaxation, thereby improving cardiac function.

Vasoactive intestinal peptide has been difficult to develop as a therapeutic agent because its half-life in the body is less than 1 minute. However, ImmunoForge has developed a first-in-class new drug with an increased half-life of 60 hours by combining it with the ELP platform, a long-acting drug platform, and selectively acting on vasoactive intestinal peptide receptor 2 (VPAC2) while avoiding gastrointestinal side effects such as diarrhea of vasoactive intestinal peptide receptor 1 (VPAC1). The effect of suppressing cardiac dysfunction was confirmed in a non-clinical MDX mouse model conducted in the United States, and following this approval for phase 2 clinical trials, phase 2 clinical trials are scheduled to be conducted in the United States and Korea.

The most common cause of death for DMD (Duchenne Muscular Dystrophy) patients was respiratory failure, but due to improvements in respiratory care and other treatments, cardiomyopathy is emerging as the main cause of death for these patients rather than respiratory failure. Deficiency of cardiac dystrophin protein impairs calcium channel function, which plays an important role in muscle contraction, leading to an increase in intracellular calcium, which in turn increases protein-degrading enzymes and causes protein degradation. This leads to muscle fiber and cell necrosis, and most patients develop cardiomyopathy in their 30s. It is estimated that there are currently 500,000 DMD patients worldwide, and since more than 80% of DMD patients die from this cardiomyopathy, if proper treatments are developed in the future, the DMD cardiomyopathy treatment market is expected to reach tens of trillions. Current treatments, such as beta-blockers and calcium channel blockers, can reduce heart rate and myocardial contractility, but there is no treatment for long-term and fundamental myocardial improvement.

ImmunoForge’s co-CEOs Sung-Min Ahn and Kiho Chang said, “Based on this US FDA approval for phase 2 clinical trials, we expect to confirm the therapeutic effect of Pemziviptadil in phase 2 clinical trials and thereby secure an unrivaled position in the DMD cardiomyopathy treatment market, where there is currently no appropriate treatment.” He added, “As many overseas companies are currently showing interest in Pemziviptadil, we will actively pursue collaborative models such as joint development and technology transfer.”

Pemziviptadil is a new drug that is expected to be effective not only for DMD cardiomyopathy but also for other heart diseases such as heart failure (HF) and pulmonary arterial hypertension (PAH) through nonclinical studies and various phase 1 clinical trials and has received orphan drug designation (ODD) for pulmonary arterial hypertension in addition to DMD cardiomyopathy from the US FDA. Meanwhile, Pemziviptadil was selected for a strategic technology-type international joint technology development project by the Korea Institute for Advancement of Technology in 2023 and is receiving a total of KRW 3 billion in support until 2026.

Around the same time, ImmunoForge also announced that it has received approval for the phase 1 clinical trial IND for ‘KF1601 (development code name)’, a treatment for Chronic Myelogenous Leukemia (CML), from the Korea Ministry of Food and Drug Safety.

KF1601 is a novel synthetic oral TKI targeted therapy that inhibits BCR::ABL1. It effectively inhibits the T315I mutation during the nonclinical development process and exhibits excellent safety and tolerability. It is expected to be a treatment that can be used more universally than existing CML treatments, and it is expected to contribute to managing chronic myeloid leukemia as a chronic disease that can overcome resistance by replacing existing treatments.

Chronic myeloid leukemia is a blood cancer that is caused by the excessive proliferation of myeloid cells and inhibition of apoptosis of BCR::ABL1 tyrosine kinase, which is expressed as a result of the Philadelphia chromosome (Philadelphia chromosome (Ph) abnormality caused by the fusion between the Abelson (Abl) tyrosine kinase gene on chromosome 9 and the Breakpoint Cluster Region (Bcr) gene on chromosome 22, a chimeric oncogene. CML accounts for approximately 30% of the total adult leukemia incidence, and it presents differently depending on age, gender, and region, and is reported to occur in approximately 0.4 to 1.75 cases per 100,000 people per year. Especially, ImmunoForge’s KF1601 has the effect of simultaneously inhibiting FLT3 in the Blast Phase patient group, and this effect was announced at the Molecular Cancer Society last year, so it is expected to be a differentiating point for KF1601 in CML drugs.

ImmunoForge’s co-CEOs Sung-min Ahn and Kiho Chang said, “Based on this Phase 1 IND approval, we plan to confirm the safety of KF1601 in the Phase 1 clinical trial and develop it targeting the global market including the US and Europe in addition to Korea.” They added, “Based on the development results, we plan to participate in academic conferences and global partnering events and actively pursue technology transfers with global pharmaceutical companies.” ImmunoForge is currently in discussions with several domestic and foreign companies.

Meanwhile, ImmunoForge is currently in the process of Series C funding and plans to apply for a technology assessment by the end of this year and pursue a KOSDAQ listing next year.

Triller Downloads Skyrocket Ahead of TikTok Ban

LOS ANGELES, Jan. 14, 2025 /PRNewswire/ — Triller, a creator-focused social media platform, has jumped more than 100 spots on the Apple App download chart as users look for a new home ahead of the TikTok ban, set to go into effect January 19, 2025.

Under the leadership of Sean Kim, a former TikTok executive who took the helm as CEO of the Triller App in November, the number of daily new users has doubled. User growth is expected to continue to accelerate.

Triller’s savemytiktoks.com utilizes Triller’s Amplify.ai technology, enabling creators to seamlessly migrate their content directly to their Triller profile.

“Having navigated the dynamic landscapes of both TikTok and Amazon Prime, I recognize the vital importance of creator empowerment, community, and commerce.” said Sean Kim, CEO of the Triller App. “The response to our ‘Save my TikToks’ campaign has been overwhelming, highlighting the great need in the industry for an app that supports creators and their work. At Triller, we are building a revolutionary platform that truly puts creators first. The next generation of the app is about giving creators the tools, ownership, control, freedom, and monetization opportunities they’ve always deserved.”

For more details, please visit savemytiktoks.com.

Triller Corp is owned by Triller Group Inc.

About Triller Group Inc.

Triller Group is a US-based company that operates two main businesses: the newly merged US- based social media operations (Triller Corp.), and the legacy operations of the Company in Hong Kong (“AGBA”).

Triller Corp. is a next generation, AI-powered, social media and live-streaming event platform for creators. Pairing music culture with sports, fashion, entertainment, and influencers through a 360-degree view of content and technology, Triller Corp. uses proprietary AI technology to push and track content virally to affiliated and non-affiliated sites and networks, enabling them to reach millions of additional users. Triller Corp. additionally owns Triller Sports, Bare-Knuckle Fighting Championship (BKFC); Amplify.ai, a leading machine-learning, AI platform; and TrillerTV, a premier global PPV, AVOD, and SVOD streaming service. For more information, visit www.triller.co.

Established in 1993, AGBA is a leading, multi-channel business platform that offers a broad set of financial services and healthcare products to consumers through a tech-led ecosystem, enabling clients to unlock the choices that best suit their needs. The Group is organized into four market- leading businesses: Platform Business, Distribution Business, Healthcare Business, and Fintech Business. For more information, please visit www.agba.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the outcome of any legal proceedings that may be instituted against us following the consummation of the business combination; expectations regarding our strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and our ability to invest in growth initiatives and pursue acquisition opportunities; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Hong Kong and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

Investor & Media Relations:

Bethany Lai
ir@triller.co

Breanne Fritcher
triller@wachsman.com